Claritas Financial Statements From 2010 to 2025
| CLAZF Stock | USD 0.0001 0.00 0.00% |
Check Claritas Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Claritas Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Claritas financial statements analysis is a perfect complement when working with Claritas Pharmaceuticals Valuation or Volatility modules.
Claritas |
Claritas Pharmaceuticals Company Shares Outstanding Analysis
Claritas Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Claritas Pharmaceuticals Shares Outstanding | 36.59 M |
Most of Claritas Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Claritas Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Claritas Pharmaceuticals has 36.59 M of shares currently outstending. This is 79.73% lower than that of the Healthcare sector and 65.76% lower than that of the Biotechnology industry. The shares outstanding for all United States stocks is 93.6% higher than that of the company.
Claritas Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Claritas Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Claritas Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Claritas Pharmaceuticals competition to find correlations between indicators driving Claritas Pharmaceuticals's intrinsic value. More Info.Claritas Pharmaceuticals is rated second in return on equity category among its peers. It also is rated second in return on asset category among its peers reporting about 0.04 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Claritas Pharmaceuticals is roughly 23.50 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Claritas Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Claritas Pharmaceuticals Financial Statements
Claritas Pharmaceuticals stakeholders use historical fundamental indicators, such as Claritas Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Claritas Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Claritas Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Claritas Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Claritas Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was founded in 2014 and is headquartered in San Rafael, California. Claritas Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Claritas Pink Sheet
Claritas Pharmaceuticals financial ratios help investors to determine whether Claritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Claritas with respect to the benefits of owning Claritas Pharmaceuticals security.